Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Investor Presentation (November 2026)
29 slides from Vivani Medical's investor presentation, November 2026
Slide 1: Vivani Medical, Inc.
Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. www.vivani.com November 2026
Slide 2: Disclaimers
Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe ha
Slide 3: Vivani Medical, Inc.
Vivani Medical, Inc. Miniature implants dosed once or twice a year, designed to Nasdaq: VANI address the adherence and tolerability barriers that limit GLP-1 Phase 1 SLIM-1 trial completed therapy today - Strong safety and tolerability profile observed for NPM-139 - Encouraging delivery profile Our
Slide 4: NPM-139 is designed to address adherence and tolerability barriers to sustained GLP-1 therapy
NPM-139 is designed to address adherence and tolerability barriers to sustained GLP-1 therapy A removable, once- or twice-yearly subdermal semaglutide implant for chronic weight management Real-World GI Intolerability Adherence Gaps Existing GLP-1 Treatments1: Existing GLP-1 Treatments: >50% of pati
Slide 5: Most patients discontinue GLP-1 therapy within one year
Most patients discontinue GLP-1 therapy within one Large Retrospective Cohort Study* (N=1,911) year, limiting long-term 6 months 12 months benefits 100% Illustrative Scenario** : Percent Remaining on Therapy 75% 50%+ improvement could translate to meaningfully improved patient outcomes 50% Real-worl
Slide 6: GI side effects drive substantial levels of medical discontinuation of GLP-1 therapy
GI side effects drive substantial levels of medical discontinuation of GLP-1 therapy Nausea, vomiting and diarrhea are reported by a large share of patients across approved and late-stage GLP-1 therapies 25–44% 8–24% 9–30% Nausea Vomiting Diarrhea Reported across approved and late- Most frequent dur
Slide 7: GLP-1 (semaglutide) discontinuation leads to rapid hunger-induced weight rebound
GLP-1 (semaglutide) discontinuation leads to rapid hunger- induced weight rebound Sudden semaglutide withdrawal produces immediate rebound hunger, leading to rapid weight regain mediated by greater food consumption NPM-139 semaglutide implant is designed to keep STEP 1 Extension: Semaglutide Withdra
Slide 8: Large pharma is investing heavily in extending GLP-1 dosing intervals
Large pharma is investing heavily in extending GLP-1 dosing intervals Approved GLP-1s are Recent investments target Vivani is developing once- or dosed daily or weekly. monthly and beyond. twice-yearly dosing APPROVED TODAY WHERE PHARMA IS INVESTING (SELECT TRANSACTIONS) VIVANI NANOPORTAL (IN DEVELO
Slide 9: Company pipeline utilizing NanoPortal platform
Company pipeline utilizing NanoPortal platform If approved, Vivani products would provide a differentiated ultra-long-acting option for patients Indication Feasibility Preclinical Clinical Obesity/Weight NPM-139 Management semaglutide Type 2 Vivani NPM-133 Diabetes semaglutide Obesity/Weight Next-ge
Slide 10: NanoPortal: Good things come in small packages
NanoPortal: Good things come in small packages 01 GLP-1 implant & applicator 02 NanoPortal device elements 03 NanoPortal technology ✔ Biocompatible materials ✔ Nanotube pore size is precisely tunable to achieve near-constant release ✔ Designed to assure adherence profiles ✔ Long-term delivery ✔ Stab
Slide 11: Proprietary NanoPortal implant technology delivers smooth, near-constant drug release
Proprietary NanoPortal implant technology delivers smooth, near- constant drug release Six-month configuration avoiding peaks and troughs associated with orals, injectables and missed dosing In vitro exenatide release-rate. Day 1 timepoint includes cumulative release over the first day including a s
Slide 12: Prototype NPM-139 demonstrates sustained weight loss and delivery for a full year
Prototype NPM-139 demonstrates sustained weight loss and delivery for a full year A B explanted devices Prototype NPM-139 (semaglutide implant), prior to PK Normalized semaglutide plasma concentrations remain optimization. In Vivo Pharmacokinetics and Weight loss measurable throughout the entire 364
Slide 13: NPM-139 provides steady preclinical pharmacokinetics
NPM-139 provides steady preclinical pharmacokinetics 3 In vivo pharmacokinetics of NPM-139 (semaglutide implant) configurations in Sprague-Dawley rats. Values are mean ± SE. *n=5 through day 28; two implants removed at Day 28 for characterization, n=3 thereafter. 13
Slide 14: NPM-139 Phase 1 study design: SLIM-1
NPM-139 Phase 1 study design: SLIM-1 Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerability assessment and pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization Otherwise healthy (no T2D) Screen and Treatment (4 Weeks) EOT Randomize (~21 days) NPM-139 (se
Slide 15: SLIM-1 topline results summary
SLIM-1 topline results summary Positive safety and tolerability 0 of 10 NPM-139 subjects experienced adverse events reported as treatment related 5 of 10 Wegovy subjects experienced gastrointestinal adverse events reported as treatment related Comparable weight loss No measurable NPM-139 drug burst
Slide 16: Encouraging Translation of NPM-139 Performance in Rats to Humans in SLIM-1; Full Data Set
Encouraging Translation of NPM-139 Performance in Rats to Humans in SLIM-1; Full Data Set Data is mean ± SE. BQL reported as BQL/2. LLOQ = 5 ng/mL 16
Slide 17: Encouraging Translation of NPM-139 Performance in Rats to Humans in SLIM-1; Manufacturing Subgroup
Encouraging Translation of NPM-139 Performance in Rats to Humans in SLIM-1; Manufacturing Subgroup Data is mean ± SE. BQL reported as BQL/2. LLOQ = 5 ng/mL 17
Slide 18: Strong Gastrointestinal Safety and Tolerability Profile for NPM-139
Strong Gastrointestinal Safety and Tolerability Profile for NPM-139 Single treatment-emergent All treatment-emergent GI AEs in the SC GI AE in the implant group group (Wegovy) were reported as (NPM-139( was reported as treatment-related except for the single not treatment-related case of diarrhoea 0
Slide 19: Strong Overall Safety and Tolerability Profile for NPM-139
Strong Overall Safety and Tolerability Profile for NPM-139 Zero adverse events, 5 subjects in the SC including GI, in the implant group (Wegovy) group (NPM-139) were experienced at least reported as treatment- one GI AE reported as related treatment-related 19
Slide 20: NPM-139 Weight Loss Comparable with Wegovy Control Group
NPM-139 Weight Loss Comparable with Wegovy Control Group NPM-139 subjects (n=10) lost Wegovy subjects lost an an average of 0.67 kg (0.79%) average of 0.76 kg (0.82%) NPM-139 manufacturing subgroup (n=5) subjects lost an average of 1.54 kg (1.78%) 20
Slide 21: NPM-139 clinical and regulatory development: Near-term plan builds on recent wins
NPM-139 clinical and regulatory development: Near-term plan builds on recent wins Milestone Status Reported preclinical proof of concept with NPM-139 (semaglutide implant) August 2025 Received regulatory approval to initiate SLIM-1 clinical trial June 2026 Announced Novo Nordisk agreement to evaluat
Slide 22: Proposed NPM-139 Phase 2 study design: SLIM-2
Proposed NPM-139 Phase 2 study design: SLIM-2 Randomize Run-In (20 weeks)* Randomized Treatment Period (16 or 24 weeks) Semaglutide Implant Dose 3 Semaglutide Implant Dose 2 2.4 mg Semaglutide Implant Dose 1 1.7 mg 1.0 mg Placebo (sham implant) 0.5 mg Semaglutide 0.25 mg Wegovy® (semaglutide injecti
Slide 23: NanoPortal retatrutide implant provides steady preclinical pharmacokinetics
NanoPortal retatrutide implant provides steady preclinical 3 Prototype NanoPortal Retatrutide Implant, pharmacokinetics n=12 (through day 28), n=9 (day 28 to 56), n=6 thereafter In vivo pharmacokinetics of prototype NanoPortal retatrutide implant in Sprague-Dawley rats in an ongoing study. Values ar
Slide 24: Patient and prescriber market research signals strong adoption potential for an ultra-long-acting GLP-1 implant
Patient and prescriber market research signals strong adoption potential for an ultra-long-acting GLP-1 implant Currently on a GLP-1 therapy (n=324) Patient market research 56% of GLP-1 patients responded “likely” 11% 33% 42% 14% or “definitely” to get a GLP-1 implant if FDA approved, prescriber rec
Slide 25: Contraception analog supports strong adoption potential for an ultra-long-acting GLP-1 implant
Contraception analog supports strong adoption potential for an ultra-long-acting GLP-1 implant THE CONTRACEPTION MARKET: AN ANALOG FOR GLP-1s Both require chronic dosing, with options spanning daily oral pills and long-acting implants. Among U.S. women ages 15–49 using a prescription contraceptive d
Slide 26: The Vivani executive leadership team
The Vivani executive leadership team Donald Dwyer, MBA Lisa Porter, MD Chief Business Officer Chief Medical Officer Former Executive Director at AstraZeneca with leadership Former Chief Medical Officer for Eiger roles in regulatory affairs, drug development, commercial BioPharmaceuticals and Dan
Slide 27: Vivani headquarters and GMP manufacturing facility
Vivani headquarters and GMP manufacturing facility 27
Slide 28: Guaranteed adherence. Better outcomes.
Guaranteed adherence. Better outcomes. Only GLP-1 implant in development for obesity, chronic weight management, and type 2 diabetes Significant improvements in adherence, tolerability and convenience expected to address primary GLP-1 market challenges today and in the future Unique opportunity alig
Slide 29: Thank You
Thank You Company Contact: Donald Dwyer, Chief Business Officer info@vivani.com Investor Relations Contact: Jami Taylor, Investor Relations Advisor investors@vivani.com www.vivani.com
Vivani Medical — Investor Presentation (November 2026) on 6ix